2seventy bio (TSVT) Stock Price, News & Analysis

-0.36 (-7.78%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
470,190 shs
Average Volume
984,997 shs
Market Capitalization
$219.09 million
P/E Ratio
Dividend Yield
Price Target

2seventy bio MarketRank™ Stock Analysis

Analyst Rating
2.38 Rating Score
208.4% Upside
$13.17 Price Target
Short Interest
14.29% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Acquiring Shares
$3.14 M Bought Last Quarter
Proj. Earnings Growth
From ($1.39) to $0.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.27 out of 5 stars

Medical Sector

306th out of 907 stocks

Pharmaceutical Preparations Industry

134th out of 418 stocks

TSVT stock logo

About 2seventy bio Stock (NASDAQ:TSVT)

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

TSVT Stock Price History

TSVT Stock News Headlines

One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
2seventy bio Inc Ordinary Shares
One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
Bristol Myers Wins FDA Nod for Abecma
See More Headlines
Receive TSVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$100.39 million
Book Value
$5.04 per share


Free Float
Market Cap
$219.09 million
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

TSVT Stock Analysis - Frequently Asked Questions

Should I buy or sell 2seventy bio stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares.
View TSVT analyst ratings
or view top-rated stocks.

What is 2seventy bio's stock price target for 2024?

8 brokers have issued 1-year target prices for 2seventy bio's shares. Their TSVT share price targets range from $5.00 to $26.00. On average, they predict the company's stock price to reach $13.17 in the next year. This suggests a possible upside of 208.4% from the stock's current price.
View analysts price targets for TSVT
or view top-rated stocks among Wall Street analysts.

How have TSVT shares performed in 2024?

2seventy bio's stock was trading at $4.27 on January 1st, 2024. Since then, TSVT shares have increased by 0.0% and is now trading at $4.27.
View the best growth stocks for 2024 here

Are investors shorting 2seventy bio?

2seventy bio saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,810,000 shares, an increase of 29.7% from the March 15th total of 5,250,000 shares. Based on an average daily trading volume, of 1,450,000 shares, the days-to-cover ratio is presently 4.7 days. Approximately 14.3% of the company's stock are short sold.
View 2seventy bio's Short Interest

When is 2seventy bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our TSVT earnings forecast

How were 2seventy bio's earnings last quarter?

2seventy bio, Inc. (NASDAQ:TSVT) posted its earnings results on Tuesday, March, 5th. The company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.11. The firm earned $10.68 million during the quarter, compared to the consensus estimate of $13.91 million. 2seventy bio had a negative trailing twelve-month return on equity of 59.19% and a negative net margin of 216.73%. During the same quarter in the prior year, the firm earned ($0.60) EPS.

What ETFs hold 2seventy bio's stock?
Who are 2seventy bio's major shareholders?

2seventy bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wedmont Private Capital (0.17%). Insiders that own company stock include Casdin Capital, Llc, Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III.
View institutional ownership trends

How do I buy shares of 2seventy bio?

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TSVT) was last updated on 4/25/2024 by Staff

From Our Partners